Zobrazeno 1 - 10 of 31 pro vyhledávání: '"H. Verdaguer"'
2
Advances in the systemic treatment of therapeutic approaches in biliary tract cancer
Autor: O. Mirallas, D. López-Valbuena, D. García-Illescas, C. Fabregat-Franco, H. Verdaguer, J. Tabernero, T. Macarulla
Publikováno v: Scientia
Biliary tract cancer; Molecular testing; Next-generation sequencing Cáncer del tracto biliar; Pruebas moleculares; Secuenciación de nueva generación Càncer del tracte biliar; Proves moleculars; Seqüenciació de nova generació Introduction Bilia
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c5207469f783ed2f54847627a36da218
https://pubmed.ncbi.nlm.nih.gov/35696747
Zobrazit plný text záznamu
8
Akademický článek
Neoadjuvant sunitinib plus exemestane in post-menopausal women with hormone receptor-positive/HER2-negative early-stage breast cancer (SUT_EXE-08): a phase I/II trial.
Autor: Fullana B; Breast Cancer Unit, Department of Medical Oncology, Catalan Institute of Oncology (ICO), L'Hospitalet de Llobregat, Barcelona, Spain., Morales S; Department of Medical Oncology, Arnau de Vilanova University Hospital, Lleida, Spain., Petit A; ProCURE Program, Catalan Institute of Oncology (ICO), OncoBell Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.; Breast Cancer Unit, Department of Pathology, Bellvitge University Hospital (HUB), L'Hospitalet de Llobregat, Barcelona, Spain., Alay A; Unit of Bioinformatics for Precision Oncology, Catalan Institute of Oncology (ICO), L'Hospitalet de Llobregat, Barcelona, Spain., Verdaguer H; Breast Cancer Unit, Department of Medical Oncology, Catalan Institute of Oncology (ICO), L'Hospitalet de Llobregat, Barcelona, Spain., Climent F; ProCURE Program, Catalan Institute of Oncology (ICO), OncoBell Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.; Breast Cancer Unit, Department of Pathology, Bellvitge University Hospital (HUB), L'Hospitalet de Llobregat, Barcelona, Spain., Navarro-Perez V; Clinical Research Unit, Catalan Institute of Oncology (ICO), L'Hospitalet de Llobregat, Barcelona, Spain., Cejuela M; Breast Cancer Unit, Department of Medical Oncology, Catalan Institute of Oncology (ICO), L'Hospitalet de Llobregat, Barcelona, Spain., Galvan P; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain., Gumà A; Breast Cancer Unit, Department of Radiology, Bellvitge University Hospital (HUB), L'Hospitalet de Llobregat, Barcelona, Spain., Llombart-Cussac A; Department of Medical Oncology, Arnau de Vilanova University Hospital, Lleida, Spain., Cordero D; Unit of Bioinformatics for Precision Oncology, Catalan Institute of Oncology (ICO), L'Hospitalet de Llobregat, Barcelona, Spain., Casanovas O; ProCURE Program, Catalan Institute of Oncology (ICO), OncoBell Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain., Prat A; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain., Gil-Gil M; Breast Cancer Unit, Department of Medical Oncology, Catalan Institute of Oncology (ICO), L'Hospitalet de Llobregat, Barcelona, Spain.; ProCURE Program, Catalan Institute of Oncology (ICO), OncoBell Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain., Pernas S; Breast Cancer Unit, Department of Medical Oncology, Catalan Institute of Oncology (ICO), L'Hospitalet de Llobregat, Barcelona, Spain. spernas@iconcologia.net.; ProCURE Program, Catalan Institute of Oncology (ICO), OncoBell Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain. spernas@iconcologia.net.
Publikováno v: Scientific reports [Sci Rep] 2024 Oct 09; Vol. 14 (1), pp. 23626. Date of Electronic Publication: 2024 Oct 09.
Zobrazit plný text záznamu
9
Akademický článek
The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer models.
Autor: Herencia-Ropero A; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Carrer Natzaret 115-117, 08035, Barcelona, Spain.; Department of Biochemistry and Molecular Biology, Autonomous University of Barcelona, Barcelona, Spain., Llop-Guevara A; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Carrer Natzaret 115-117, 08035, Barcelona, Spain. alballop@gmail.com., Staniszewska AD; Oncology R&D, AstraZeneca, Cambridge, UK., Domènech-Vivó J; Hereditary Cancer Genetics Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Carrer Natzaret 115-117, 08035, Barcelona, Spain.; Programa de doctorat en Biomedicina, Universitat de Barcelona, Barcelona, Spain., García-Galea E; Oncology Data Science Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Moles-Fernández A; Medicine Genetics Group, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.; Department of Clinical and Molecular Genetics, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Pedretti F; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Carrer Natzaret 115-117, 08035, Barcelona, Spain., Domènech H; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Carrer Natzaret 115-117, 08035, Barcelona, Spain., Rodríguez O; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Carrer Natzaret 115-117, 08035, Barcelona, Spain., Guzmán M; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Carrer Natzaret 115-117, 08035, Barcelona, Spain., Arenas EJ; Growth Factors Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer, Monforte de Lemos, Madrid, Spain.; Epigenetics Group, Josep Carreras Leukaemia Research Institute, Barcelona, Spain., Verdaguer H; Preclinical and Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.; Gastrointestinal and Endocrine Tumor Unit, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Calero-Nieto FJ; Oncology R&D, AstraZeneca, Cambridge, UK., Talbot S; Oncology R&D, AstraZeneca, Cambridge, UK., Tobalina L; Oncology R&D, AstraZeneca, Cambridge, UK., Leo E; Oncology R&D, AstraZeneca, Cambridge, UK., Lau A; Oncology R&D, AstraZeneca, Cambridge, UK., Nuciforo P; Molecular Oncology Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Dienstmann R; Oncology Data Science Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Macarulla T; Preclinical and Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.; Gastrointestinal and Endocrine Tumor Unit, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Arribas J; Growth Factors Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer, Monforte de Lemos, Madrid, Spain.; Departament of Medicine and Life Sciences, Pompeu Fabra University, Barcelona, Spain.; Catalan Institution for Research and Advanced Studies, ICREA, Barcelona, Spain.; Cancer Research Program, The Hospital del Mar Research Institute, Barcelona, Spain., Díez O; Hereditary Cancer Genetics Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Carrer Natzaret 115-117, 08035, Barcelona, Spain.; Department of Clinical and Molecular Genetics, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Gutiérrez-Enríquez S; Hereditary Cancer Genetics Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Carrer Natzaret 115-117, 08035, Barcelona, Spain., Forment JV; Oncology R&D, AstraZeneca, Cambridge, UK., O'Connor MJ; Oncology R&D, AstraZeneca, Cambridge, UK., Albertella M; Oncology R&D, AstraZeneca, Cambridge, UK., Balmaña J; Hereditary Cancer Genetics Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Carrer Natzaret 115-117, 08035, Barcelona, Spain. jbalmana@vhio.net.; Department of Medical Oncology, Vall d'Hebron Barcelona Hospital Campus, Autonomous University of Barcelona, Barcelona, Spain. jbalmana@vhio.net., Serra V; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Carrer Natzaret 115-117, 08035, Barcelona, Spain. vserra@vhio.net.
Publikováno v: Genome medicine [Genome Med] 2024 Aug 26; Vol. 16 (1), pp. 107. Date of Electronic Publication: 2024 Aug 26.
Zobrazit plný text záznamu
10
Akademický článek
Phase 2 trial of bintrafusp alfa as second-line therapy for patients with locally advanced/metastatic biliary tract cancers.
Autor: Yoo C; Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea., Javle MM; The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA., Verdaguer Mata H; Vall d'Hebron University Hospital, Barcelona, Spain., de Braud F; IRCCS National Cancer Institute Foundation, Milan, Italy., Trojan J; Goethe University Hospital, Frankfurt, Germany., Raoul JL; ICO- Site René Gauducheau, Saint-Herblain, France., Kim JW; Seoul National University Bundang Hospital, Seongnam, South Korea., Ueno M; Kanagawa Cancer Center, Yokohama, Kanagawa, Japan., Lee CK; Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea., Hijioka S; National Cancer Center Hospital, Chuo, Tokyo, Japan., Cubillo A; HM Madrid Sanchinarro University Hospital, Clara Campal Comprehensive Cancer Center, Madrid, Spain.; UCJC HM Hospital School of Health Sciences, Madrid, Spain., Furuse J; Kanagawa Cancer Center, Yokohama, Kanagawa, Japan., Azad N; The Johns Hopkins Hospital, Baltimore, Maryland, USA., Sato M; Merck Biopharma Co., Ltd., Tokyo, Japan, an affiliate of Merck KGaA, Darmstadt, Germany., Vugmeyster Y; EMD Serono, Billerica, Massachusetts, USA., Machl A; EMD Serono, Billerica, Massachusetts, USA., Bajars M; The Healthcare Business of Merck KGaA, Darmstadt, Germany., Bridgewater J; UCL Cancer Institute, London, UK., Oh DY; Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Integrated Major in Innovative Medical Science, Seoul National University Graduate School, Seoul, South Korea., Borad MJ; Mayo Clinic Cancer Center, Phoenix, Arizona, USA.
Publikováno v: Hepatology (Baltimore, Md.) [Hepatology] 2023 Sep 01; Vol. 78 (3), pp. 758-770. Date of Electronic Publication: 2023 Apr 01.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje